Welcome to DailyUpdates Neurodegenerative & Neuroelectrophysiological Disorders channel - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 2 more day(s). To receive DailyUpdates by e-mail register here

PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Neurodegenerative & Neuroelectrophysiological Disorders channel

If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work


Today's journal articles

No journal articles today

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

Design, synthesis, biological evaluation and docking study of 4 - isochromanone hybrids bearing N - benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors.

Arctigenin Suppress Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis Through AMPK and PPAR-γ/ROR-γt Signaling.

PKA Phosphorylation of NCLX Reverses Mitochondrial Calcium Overload and Depolarization, Promoting Survival of PINK1-Deficient Dopaminergic Neurons.

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, attenuates postoperative cognitive dysfunction in aging mice.

Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic marker.

A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat.

Recombinant adenovirus encoding NLRP3 RNAi attenuate inflammation and brain injury after intracerebral hemorrhage.

Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.

Role of glial 14-3-3 gamma protein in autoimmune demyelination.

Inhibition of Gli1 mobilizes endogenous neural stem cells for remyelination.

A Novel Ligustrazine Derivative T-VA Prevents Neurotoxicity in Differentiated PC12 Cells and Protects the Brain against Ischemia Injury in MCAO Rats.

Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis.

dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis.

Serotonin 5-HT7 receptor agonist, LP-211, exacerbates Na(+), K(+)-ATPase/Mg(2+)-ATPase imbalances in spinal cord-injured male rats.

PMX53 protects spinal cord from ischemia-reperfusion injury in rats in the short term.

The soluble extracellular fragment of neuroligin-1 targets Aβ oligomers to the postsynaptic region of excitatory synapses.

Neuroglobin Attenuates Beta Amyloid-Induced Apoptosis Through Inhibiting Caspases Activity by Activating PI3K/Akt Signaling Pathway.

Synthetic Small Molecules Derived from Natural Vitamin K Homologues that Induce Selective Neuronal Differentiation of Neuronal Progenitor Cells.

Synapse-specific IL-1 receptor subunit reconfiguration augments vulnerability to IL-1β in the aged hippocampus.

Brain targeted PLGA nanocarriers alleviating amyloid-Β expression and preserving basal survivin in degenerating mice model.

Today's News Items

RedHill Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis

Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreichs Ataxia (FA); First Gene Therapy Candidate to Receive Designation for FA

Training Courses & Meetings

No events listed

Previous News Items

Newron to re-submit US NDA for Xadago (safinamide) - no additional evaluation of abuse liability or dependence/withdrawal effects required

Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimers Patients with APOE4/4 Homozygous Genotype

TauRx Reports First Phase 3 Results for LMTX Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials